Conbercept vs Ranibizumab for patients with age-related macular degeneration: a prospective cohort study

Evaluation of the effectiveness, safety and cost-effectiveness of Conbercept vs Ranibizumab for patients with age-related macular degeneration

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17013023

Enrollment

Unknown

Registered

2017-10-18

Start date

2017-11-01

Completion date

Unknown

Last updated

2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration

Interventions

Conbercept-group:Conbercept

Ranibizumab-group:Ranibizumab

Eligibility

Sex/Gender

All

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients aged more than 50 years old; Patients diagnosed with wet AMD; Patients willing to be treated with the anti-VEGF agents; Patients signed informed consent and were willing to participate in this study.;Inclusion criteria: Patients aged more than 50 years old; Patients diagnosed with wet AMD; Patients willing to be treated with the anti-VEGF agents; Patients signed informed consent and were willing to participate in this study.

Exclusion criteria

Exclusion criteria: None;Exclusion criteria: None

Design outcomes

Secondary

Measure	Time frame
central retinal thickness;intraocular pressure;plasma level of VEGF;;central retinal thickness;intraocular pressure;plasma level of VEGF;	—

Primary

Measure	Time frame
best-corrected visual acuity;Quality of life;Adverse Events;;best-corrected visual acuity;Quality of life;Adverse Events;	—

Countries

China

Contacts

Public ContactJiaxing Zhang;Jiaxing Zhang ;

Guizhou Provincial People's Hospital;Guizhou Provincial People's Hospital

zjx19870619@126.com;zjx19870619@126.com+86 13984817008;+86 13984817008

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026